» Articles » PMID: 34108096

MAFLD Vs NAFLD: Where Are We?

Overview
Journal Dig Liver Dis
Publisher Elsevier
Specialty Gastroenterology
Date 2021 Jun 10
PMID 34108096
Citations 11
Authors
Affiliations
Soon will be listed here.
Citing Articles

Metabolic dysfunction-associated fatty liver disease indicates more hepatic fibrosis than nonalcoholic fatty liver disease.

Hong S, Hong Z, Hao Y, Sun L, Wei H Medicine (Baltimore). 2025; 104(6):e41455.

PMID: 39928810 PMC: 11813007. DOI: 10.1097/MD.0000000000041455.


Hepatokines and MASLD: The GLP1-Ras-FGF21-Fetuin-A Crosstalk as a Therapeutic Target.

Milani I, Codini M, Guarisco G, Chinucci M, Gaita C, Leonetti F Int J Mol Sci. 2024; 25(19).

PMID: 39409124 PMC: 11477334. DOI: 10.3390/ijms251910795.


Management of Metabolic-Associated Fatty Liver Disease/Metabolic Dysfunction-Associated Steatotic Liver Disease: From Medication Therapy to Nutritional Interventions.

Beygi M, Ahi S, Zolghadri S, Stanek A Nutrients. 2024; 16(14).

PMID: 39064665 PMC: 11279539. DOI: 10.3390/nu16142220.


Time course of western diet (WD) induced nonalcoholic steatohepatitis (NASH) in female and male Ldlr-/- mice.

Spooner M, Garcia-Jaramillo M, Apperson K, Lohr C, Jump D PLoS One. 2023; 18(10):e0292432.

PMID: 37819925 PMC: 10566735. DOI: 10.1371/journal.pone.0292432.


Therapeutic Effects of microRNAs on Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH): A Systematic Review and Meta-Analysis.

Zhu Y, Tan J, Wong S, Goon J Int J Mol Sci. 2023; 24(11).

PMID: 37298120 PMC: 10252239. DOI: 10.3390/ijms24119168.